Abstract (J Korean Assoc Oral Maxillofac Surg 2018;44:289-292) Objectives: Chronic periodontitis is a common inflammatory disease of the oral cavity that causes destruction of periodontal tissues and bone around the teeth. Sclerostin is a protein encoded by the SOST gene. In this study, gingival crevicular fluid (GCF) levels of sclerostin in patients with chronic periodontitis were compared with those of healthy subjects. Materials and Methods: In this case-control study, a total of 40 subjects were enrolled and divided into the healthy group (n=23) and chronic periodontitis group (n=17). GCF samples were collected, and the concentration of sclerostin was evaluated using enzyme-linked immunosorbent assay.
I. Introduction
Chronic periodontitis is an inflammatory disease caused by interaction between microorganisms and the host immune system 1 . When the balance between bacterial virulence and the host immune system is disturbed, periodontal disease occurs, causing alveolar bone loss and periodontal destruction 2 . Microorganisms such as Tannerella forsythia and Porphyromonas gingivalis and their metabolites are the primary etiologic factors involved in the onset of periodontitis 3 . However, the disease is exacerbated by a series of endogenous agents, such as matrix metalloproteinases and inflammatory mediators including prostaglandin E2 and tumor necrosis factoralpha, resulting in activation of the bone resorption mechanism 4 . The composition of gingival crevicular fluid (GCF) in periodontal diseases reflects the nature and extent of the host response to microbial plaques, and its evaluation provides quantitative assessment of biochemical markers for measuring cell metabolism 5 . A newly cloned gene, SOST, encodes sclerostin, a protein that is a potent inhibitor of bone formation 6 . Sclerostin reduces the viability of osteoblasts and osteocytes and consequently leads to disturbances in bone turnover 7 . Sclerostin deficiency leads to sclerosteosis and Van Buchem disease, characterized by progressive bone thickening due to increased bone formation. This protein is produced by osteocytes 8 . Moreover, sclerostin is known as a marker of mature osteocytes and affects bone metabolism by inhibiting osteoblast proliferation and differentiation 9, 10 . Considering the potential role of sclerostin in bone metabolism, and because only one study evaluated GCF level of sclerostin in patients with periodontitis, in this study, the GCF levels of sclerostin in patients with chronic periodontitis and healthy individuals were compared.
II. Materials and Methods

Study subjects
In this case-control, cross-sectional study, 40 patients, 22 males and 18 females, between 25 and 50 years of age were enrolled from 2016 to 2017 at Department Periodontics, Shahid Beheshti University of Medical Sciences (Tehran, Iran). All subjects provided written informed consent, and the institutional ethics review committee of Shahid Beheshti University of Medical Sciences approved this study (approval no. IR.SBMU.RIDS.REC.1395.335). The subjects were divided into two groups: healthy group (n=23) and chronic periodontitis group (n=17). Criteria for healthy subjects were gingival index <1, pocket depth (PD) <3 mm, and no clinical attachment loss (CAL). Patients with chronic periodontitis were selected according to the American Academy of Periodontology (AAP) criteria 1999, having at least two teeth with PD ≥5 mm and CAL ≥4 mm with bleeding on probing at the affected sites. Exclusion criteria were smoking, systemic disease (i.e., diabetes mellitus, rheumatoid arthritis, and systemic bacterial, fungal or viral infection), pregnancy, or history of drug therapy or periodontal therapy during the past 6 months. Periodontal examination was performed by the same periodontist.
Sampling
The sampled teeth were isolated with cotton and air dried. Supragingival plaque was removed carefully with a sterile scaler. GCF samples were collected from two locations, with the deepest PD achieved by placing paper points (#25) using the intrasulcular method. Samples were ensured to be free of saliva or blood and immediately transferred to sterile microtubes containing 250 μL phosphate-buffered saline. All samples were centrifuged at 4 o C and 3,000g for 10 minutes. The supernatant was collected and immediately frozen at -70 o C until subsequent analysis.
Sclerostin measurement
The total concentration of sclerostin was measured using a commercially available enzyme-linked immunosorbent assay kit (Thermo Fisher Scientific, Waltham, MA, USA). All procedures were performed in duplicate according to the manufacturer's instructions. Optical densities at 450 nm were measured (reference wavelength 570 nm). Next, sclerostin concentration in the GCF was determined by comparing the average absorbance readings of each sample with the concentrations in the assay standard curve.
Statistical analysis
Statistical analysis was conducted using IBM SPSS Statistics software (ver. 21; IBM Co., Armonk, NY, USA). In addition, Mann-Whitney U test was used to examine the relationship between sclerostin levels in the patient and healthy groups. P<0.005 was considered statistically significant. Data are presented as the mean±standard deviation.
III. Results
Median and mean values of GCF concentration of sclerostin in both healthy and patient groups are outlined in Table 1 and Fig. 1 . Statistical results showed a significant difference in the concentration of sclerostin in patients with chronic periodontitis compared with the healthy subjects (P<0.005). 
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IV. Discussion
Chronic periodontitis is a common inflammatory disease of the oral cavity resulting in destruction of periodontal tissues and bone surrounding the teeth. To date, many studies have been conducted on the assessment of inflammatory status caused by interaction of the host immune system and cytokines and interleukins in the development of chronic periodontitis 11 . However, only a few studies have focused on the role of GCF proteins such as sclerostin and their effects on bone metabolism in vivo and in vitro.
Since the physiology of bone metabolism is based on a pivotal equilibrium between osteoblasts and osteoclast cells, the focus of most studies is the axial relationship of these cells and their direct function on formation, density, and volume of bone in the body 12, 13 , with less attention to GCF proteins and their role in diagnosis and prognosis of periodontal disease.
GCF composition reflects the periodontal inflammatory status as a result of the interplay between the bacterial biofilm and periodontal tissues. Collection of GCF could be a good alternative to invasive diagnostic methods, including serum samples or gingival biopsies 5 . GCF assessment is quick, easy to perform, feasible at all tooth sites, and, most importantly, produces no or little trauma to gingival tissues 14 .
The results of this study showed the mean GCF level of sclerostin in patients with chronic periodontitis was significantly higher than that in healthy subjects (P<0.005) and is in agreement with a similar study in which the sclerostin level and the ratio of receptor activator of nuclear factor-κB ligand (RANKL) to osteoprotegerin (OPG) in GCF of periodontal diseases were examined; the GCF level of sclerostin may be more reliable than the RANKL/OPG ratio as a diagnostic and prognostic marker of periodontal disease and treatment outcome 12 .
In most studies, chronic periodontitis phenotype and bone resorption were associated with discovery of the SOST gene 11 . Administration of sclerostin antibody in ovariectomized mice and monkeys resulted in dose-dependent increases in bone volume and density, as well as bone formation on trabecular, periosteal, and endosteal surfaces 15, 16 . Sclerostin may be linked with periodontal disease and is potentially a strong candidate for bone protection and an effective therapeutic target for treatment of periodontal diseases. Therefore, it may be possible to use different strategies and therapeutic approaches in the near future to control periodontal disease and prevent bone destruction.
In studies conducted using placebo and single dose antisclerostin antibodies, a potential therapeutic benefit was observed in patients with bone resorption and those with rheumatoid arthritis 17 . Therefore, anti-sclerostin antibodies could prevent bone resorption in the body and, in bone marrow spaces, were associated with bone formation and increased differentiation of osteoblasts 18 . Conversely, deletion of the sclerostin gene inhibits the Wnt/β-catenin signaling pathway and results in positive and constructive signals for PDL fiber reconstruction, which can be attributed directly to the presence of Sharpey fibers 11, 17 . Regarding the complex interaction of the host immune system, including cytokines, interleukins, and bacterial agents, it is difficult to understand the role of sclerostin in the extent and severity of periodontal disease. Additional studies are required to better understand the roll of sclerostin in periodontal disease.
IV. Conclusion
Although there have been many limitations in previous studies, sclerostin can be a possible marker for assessment of periodontal health status. Hopefully in the near future, more progress will be made in this important area.
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